Abstract
A new monoclonal antibody Ber-MAC3 is reported. It recognises a formol sensitive epitope of a not yet clustered monocyte/macrophage specific 140 kilodalton glycoprotein that is expressed on the cell surface and in the cytoplasm. In 30 cases of acute and chronic leukaemia, Ber-MAC3 staining was restricted to 15 myeloid leukaemias of M4 and M5 types. The tumour cells of two cases of true histiocytic malignancies were Ber-MAC3 positive, whereas those of all 280 malignancies of lymphocytic origin were negative. The latter included 52 cases of Hodgkin's disease and 41 cases of Ki-1 positive anaplastic large cell lymphomas which had previously been classified as true histiocytic lymphomas. Ber-MAC3 therefore seems to be of considerable value for selective identification of monocytes and macrophages at a certain stage of differentiation and seems to be suitable for diagnosing myelomonocytic or monocytic leukaemia and neoplasms of true histiocytic origin.
Cite
CITATION STYLE
Backe, E., Schwarting, R., Gerdes, J., Ernst, M., & Stein, H. (1991). Ber-MAC3: New monoclonal antibody that defines human monocyte/macrophage differentiation antigen. Journal of Clinical Pathology, 44(11), 936–945. https://doi.org/10.1136/jcp.44.11.936
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.